Streetbeat News

Partnerships

MXCT

MaxCyte, Inc. (NASDAQ:MXCT) and Vittoria Biotherapeutics have signed a strategic platform license (SPL) for MaxCyte's Flow Electroporation technology and ExPERT platform. Vittoria will obtain non-exclusive clinical and commercial rights to use the technology and platform, while MaxCyte will receive licensing fees and program-related revenue. Vittoria plans to file an investigational new drug application for their lead program, Viper 101, later this year.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:06 pm

GLMD

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has announced a strategic partnership with OnKai to apply its artificial intelligence (AI) models for enrollment and execution of clinical trials in underserved communities. The collaboration will start with Galmed's Primary Sclerosing Cholangitis (PSC) clinical development program. The clinical development for PSC is expected to start with a Phase 2a study in the fourth quarter of 2023. OnKai's AI platform is anticipated to generate a comprehensive enrollment plan for each trial phase and support the trial in local clinics.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:06 pm

ICAD

iCAD, Inc. (NASDAQ:ICAD) is showcasing its ProFound AI Suite for breast cancer detection at the AHRA 2023 annual meeting. The suite includes ProFound AI Detection®, ProFound AI® Density Assessment, and ProFound AI® Risk. The company is also offering an ROI tool to help organizations measure the return on investment for adopting ProFound AI. Several healthcare providers, including Midstate Radiology Associates, Kettering Health, and Naugatuck Valley Radiology, have reported increased efficiency, standardized assessments, and improved patient care after adopting iCAD's solutions.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:05 pm

PRTK

Paratek Pharmaceuticals has announced a modification to its Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA). The modification provides new development milestones for the next procurement of NUZYRA, a treatment for pulmonary anthrax. The next procurement will be split into two equal parts based on the achievement of specific development milestones. The first procurement will be triggered by positive data from a dose-ranging efficacy study in 2024. The second procurement will be triggered by positive data from two studies in 2024. The final procurement will be triggered by Paratek's receipt of sNDA approval from the FDA for the treatment of inhalation anthrax.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:04 pm

CBAT

CBAK Energy has announced a three-year partnership with Echom for a lithium-ion battery order worth RMB 180 million. The partnership is expected to boost CBAK Energy's revenues and market presence.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 12:01 pm

TDY

Mobilicom has received a commercial scale purchase order from Teledyne-FLIR for the initial production of drones for the US Department of Defense. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:18 am

FULC

Fulcrum Therapeutics has entered into an exclusive license agreement with CAMP4 Therapeutics for novel therapeutic agents against an undisclosed target for Diamond-Blackfan Anemia. The deal includes an undisclosed upfront payment and up to $70M in additional payments.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:15 am

GSK

Elsie Biotechnologies has entered into a research collaboration agreement with GSK to advance the discovery and development of Elsie's Oligonucleotide Discovery Platform. The deal includes an upfront payment to Elsie and potential development and commercial milestones. The terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:11 am

BGNE

BeiGene (NASDAQ:BGNE) and DualityBio have announced a partnership to advance a differentiated antibody drug conjugate (ADC) therapy for solid tumors. BeiGene will acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:08 am

GSK

Elsie Biotechnologies has announced a research collaboration with GSK plc (NYSE:GSK) to advance the discovery and development of Elsie’s oligonucleotide discovery platform. The collaboration will combine GSK's expertise in DNA encoded library technologies with Elsie's drug discovery platform. GSK may exercise an option to a non-exclusive license from Elsie for the discovery platform and P(V) chemistry technologies.

Portfolio Pulse from Charles Gross

July 10, 2023 | 11:05 am